ADVOCATE. CONNECT. INNOVATE.

2018 BioPacific Conference

San Mateo

6/23/2018

8:00am - 7:00pm

2018 BioPacific Conference

Theme: Innovation, Collaboration and Globalization
This conference will showcase:

- Winners of 2018 CABS K. Fong Award in Life Sciences
- Expected to attract more than 500 attendees of life science professionals from the US, China and other regions
- Opportunities to connect with your peers and potential clients
- Cutting-edge science and technology in life sciences including cancer immunotherapy, cell therapy, precision medicine, and medical technology
- Success stories of entrepreneurs and emerging companies
- Patent and legal considerations in life sciences
- Latest biopharmaceutical development policies and regulations
- Cross-border investment and M&A and in life sciences
- BioPartnering Forum to facilitate interactions including project introduction and talent recruitment

Please see the list of speakers and panelists below.
Please contact fundraising@cabsweb.org if you are interested in sponsorship.

For registration information, please visit the event page at https://lnkd.in/gPzf2Kb

Confirmed Speakers and Panelists include:
- Nils Lonberg, PhD, Senior VP, Oncology Discovery Biology, Bristol-Myers Squibb
- Chris Chen, PhD, CEO, WuXi Biologics
- Sylvaine Cases, PhD, Vice President, Oncology Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson
- Li Zhu, PhD, Chief Strategy Officer, Nanjing Legend Biotech and GenScript Biotechnology
- Deborah Charych, PhD, Executive Director, Nektar Therapeutics
- Dan Zhang, MD, MA, MPH, Chairman, Fountain Medical Development (FMD)
- Guoliang Yu, PhD, Executive Chairman, Crown Bioscience; Venture Partner, OrbiMed Venture
- Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar Biosciences
- Scott Liu, PhD, President and CEO, Shanghai Henlius Biotech, Inc.
- Yiding(Mike)Chen, Founder and CEO, ACROBiosystems
- Janet Xiao, PhD, JD, Partner, Co-chair, Global Life Sciences Group, Morrison & Foerster
- Li Feng, PhD, Partner, Finnegan
- Tony Xue, PhD, CEO, Kelun-Biotech BioPharmaceutical
- Wilson Lee, Director, Sino-Singapore (Chengdu) Innovation Park Development
- Daniel Pierce, PhD, Senior Director of Translational Medicine, Celgene
- Kenneth Fong, PhD, Chairman, Kenson Ventures
- Qingcong Lin, PhD, CEO, BioCytogen
- Tao Chen, Co-founder and CEO of Paragon Genomics
- Xueheng (Shawn) Cheng, PhD, Chief Technology Officer, Viva Biotech Ltd.
- John Ning, MD, PhD, Clinical Consultant in Clinical Science and Product Development Oncology for Genentech
- Jimmy Zhang, PhD, MBA, Venture Partner, Lilly Asian Ventures
- Cheni Kwok, PhD, CLP, Managing Partner & Founder, Linear Dreams
- Steven X. Cui, PhD, JD, Owner, TransPac IP
- Huijun Zhou, PhD, Founder and CEO, iDNA
- Grace Xu, MBA, Chairperson, Dendreon; Senior Vice President, Sanpower Group
- Liyu Wu, PhD, Senior Director, US Pharmaceutical Business Development and Project Management, Novogene
- Brooke Rock, PhD, Principal Scientist, Amgen
- Panelist, Rufus Pichler, JD, Partner, Morrison & Foerster
- Panelist, Jingrong Li, PhD, VP of CMC/Manufacturing, CStone (Suzhou) Pharmaceuticals
- Panelist, Rajeev Dadoo, PhD, Partner, SR One
and more

Conference Agenda
8:00 AM – 8:45 AM: Registration

8:45 AM – 8:50 AM: Welcome Remarks
- Yan Wang, PhD, President-elect of CABS and 2018 BioPacific Conference Organizing Committee Chair

8:50 AM – 9:00 AM: State of the Society
- Alex J. Zhang, PhD, MBA, President of CABS

9:00 AM – 9:30 AM
Combining Discreet Immune Mechanisms for Cancer Therapy: From Concept to Clinical Evidence
- Nils Lonberg, PhD, Senior VP, Oncology Discovery Biology, Bristol-Myers Squibb

9:30 AM – 10:00 AM
In-China-for-Global Biologics: The Exciting Story of WuXi Biologics
- Chris Chen, PhD, CEO, WuXi Biologics

10:00 AM-10:15 AM
Coffee Break

10:15 AM-10:55 AM
CABS K. Fong Award in Life Sciences
- Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures
Awardees:
- Guoliang Yu, PhD, Executive Chairman, Crown Bioscience; Venture Partner, OrbiMed Venture
- Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar Biosciences

10:55 AM – 11:15 AM: Fireside Chat:
Moderator: Cheni Kwok, PhD, CLP, Managing Partner & Founder, Linear Dreams
- Yiding(Mike)Chen, Founder and CEO, ACROBiosystems
- Scott Liu, PhD, President and CEO, Shanghai Henlius Biotech, Inc.

11:15 AM – 11:55 PM
IP Considerations, and Cross-border Licensing and Collaboration
This session will cover intellectual property considerations in drug development and licensing deals; the stories of cross-border licensing deals and collaborations in drug and device development.
Moderator, Janet Xiao, PhD, JD, Partner, Co-chair, Global Life Sciences Group, Morrison & Foerster
- Panelist, Li Feng, PhD, Partner, Finnegan
- Panelist, Tony Xue, PhD, CEO, Kelun-Biotech BioPharmaceutical
- Panelist, Wilson Lee, Director, United States, Sino-Singapore (Chengdu) Innovation Park Development
- Panelist, Steven X. Cui, PhD, JD, Owner, TransPac IP
- Panelist, Rufus Pichler, JD, Partner, Morrison & Foerster

12:00 PM – 12:45 PM
Lunch Break

12:45 PM – 1:00 PM
Celebrating 20 years of CABS’s Excellence

1:00 PM – 1:30 PM
Presentation title will be available later
- Sylvaine Cases, PhD, Vice President, Oncology Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson

1:30 PM – 1:55 PM
Innovations, Tools, and Animal Models in Drug Development
This session will cover humanized animal model for immune checkpoint inhibitor evaluation; how to design clinical trial based on animal model; the importance of NGS and liquid biopsy in precision medicine and drug development; and affinity selection mass spectrometry as an innovative platform.
- Panelist, Brooke Rock, PhD, Principal Scientist, Amgen
- Panelist, Qingcong Lin, PhD, CEO, BioCytogen Boston
- Panelist, Tao Chen, Co-founder and CEO of Paragon Genomics
- Panelist, Xueheng (Shawn) Cheng, PhD, Chief Technology Officer, Viva Biotech
- Panelist, Liyu Wu, PhD, Senior Director, US Pharmaceutical Business Development and Project Management, Novogene

2:00 PM – 2:30 PM
A world-class breakthrough in blood cancer treatment done by China biotech company Legend Biotech with CART cell therapy
- Li Zhu, PhD, Chief Strategy Officer, Nanjing Legend Biotech and GenScript Biotechnology

2:30 PM – 3:00 PM
Developing Innovative Therapeutics
This session will cover the program selection for drug development; clinical trial strategies on immune-oncology drug; companion diagnostics for a successful clinical trial.
- Panelist, Daniel Pierce, PhD, Senior Director of Translational Medicine, Celgene
- Panelist, John Ning, MD, PhD, Clinical Consultant in Clinical Science and Product Development Oncology for Genentech
- Panelist, Jingrong Li, PhD, VP of CMC/Manufacturing, CStone (Suzhou) Pharmaceuticals

3:00 PM – 3:15 PM
Coffee Break

3:15 PM – 3:45 PM
The regulatory affairs after the enforcement of ICH guideline by CFDA and the comparison of regulatory affairs between China and US
- Dan Zhang, M.D., MA, MPH, Chairman, Fountain Medical Development (FMD)

3:45 PM – 4:15PM
Harnessing potent immune agonist pathways for oncology and beyond
- Deborah Charych, PhD, Executive Director, Nektar Therapeutics

4:15 PM – 4:50 PM
Panel Discussion: Investment, Acquisition and IPO in Life Sciences. This session will cover cross-border life science investment, Sanpower’s acquisition of Dendreon for $819.9 million; IPO in Hongkong vs. US.
Moderator, Huijun Zhou, Ph.D., FACMG, Founder and CEO, iDNA
- Panelist, Jimmy Zhang, PhD, MBA, Venture Partner, Lilly Asian Ventures
- Panelist, Grace Xu, MBA, Chairperson, Dendreon; Senior Vice President, Sanpower Group
- Panelist, Deloitte
- Panelist, Rajeev Dadoo, PhD, Partner, SR One

5:00 PM: Conference Adjourned
-------------------------------------------------------------------------------------------

VIP speaker bio and presentation abstract (more later)

Nils Lonberg, Ph.D.
Senior VP, Oncology Discovery Biology, Bristol-Myers Squibb
Bio: Dr. Lonberg is Senior VP, Oncology Discovery Biology at Bristol-Myers Squibb, where he leads drug discovery efforts for both targeted oncology agents and immuno-oncology agents. Dr. Lonberg began his career in the biotech/pharmaceutical industry leading the research group at GenPharm International that developed genetically engineered strains of mice with germline-configuration human immunoglobulin genes. These transgenic animals have been used to discover over three dozen clinical-stage human sequence antibodies, including ten FDA approved products (golimumab, ustekinumab, ofatumumab, canakinumab, ipilimumab, nivolumab, secukinumab, daratumumab, bezelotoximab, and olaratumab). In 1997, GenPharm was acquired by Medarex, which was in turn acquired by Bristol-Myers Squibb in 2009. Beginning in 1998, Dr. Lonberg’s research group focused on antibody therapies that target and modulate immune attenuating pathways to activate patient immune responses to cancer cells (so-called “checkpoint blockade” therapies). Ipilimumab, which began clinical testing in 2000, was the first ever checkpoint blockade cancer therapy to enter clinical development and to gain regulatory approval. Ipilimumab, which gained regulatory approval in 2011, was also the first drug to ever demonstrate a survival benefit for patients with metastatic melanoma in a randomized clinical trial. A second checkpoint blockade cancer therapeutic from Dr. Lonberg’s group, nivolumab, entered clinical development in 2006 and gained regulatory approval in 2014. Dr. Lonberg received his Ph.D. in Biochemistry & Molecular Biology from Harvard University in 1985, where he studied under Professor Walter Gilbert, and he was a post-doctoral fellow at Memorial Sloan-Kettering Cancer Center. Dr. Lonberg was elected to the National Academy of Engineering in 2015.

Presentation Title: Combining Discreet Immune Mechanisms for Cancer Therapy: From Concept to Clinical Evidence

Abstract: The cancer immunotherapy drugs ipilimumab and nivolumab target the immune checkpoint molecules CTLA-4 and PD-1 respectively. While both targets are mediators of immune attenuation, preclinical, and now clinical, data clearly demonstrate that ipilimumab and nivolumab have very different mechanisms of action. The combination of these discreet mechanisms showed early promise in preclinical assays and models. That data led to clinical testing of the combined use of both drugs in multiple different cancer types. The combination is now FDA approved in melanoma and kidney cancer, with clinical development continuing in a variety of other cancers. The mechanism of action of this now validated therapy will be discussed.

Chris Chen, PhD
CEO, WuXi Biologics
Bio: Dr. Chris Chen is currently Chief Executive Officer at WuXi Biologics, a Hong Kong listed public company with market cap of approx. $10+ billion USD. At WuXi he has built a world-class open-access integrated biologics discovery, development and manufacturing platform enabling full spectrum of companies ranging from 2-employee virtual companies to Top 20 global large pharma. WuXi has transformed the global biotech industry by enabling entrepreneurs to build successful biotech companies with no need for investing in infrastructure for people, labs or manufacturing. Under his leadership, WuXi has assembled one of the largest biologics teams with over 2700 scientists enabling 60+ biologics entering into clinical trials per year. WuXi has also pioneered disposable-bioreactor based state-of-the-art commercial manufacturing facility and built the first 30,000L bioreactor capacity in the world using disposables. The globally leading platform developed by WuXi Biologics is now serving more than 200 companies worldwide.

Dr. Chen obtained his dual bachelor’s degrees of chemical engineering and automation at Tsinghua University, Beijing China and his Ph.D. in chemical engineering at the University of Delaware, US. He then gained valuable experience in biologics development, manufacturing and quality in the US, where his previous assignments include director and manager positions at Lilly and Merck. Dr. Chen later joined Shanghai Celgen Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar etanercept and obtained regulatory approval for the program in China in 2011. He chaired multiple conferences in biochemical engineering and mab development in US and China and is frequently invited to speak at multiple conferences. He is also adjunct professor at Shanghai Jiaotong University. Dr Chen is co-author and co-inventor of 60+ publications and patents.

Presentation Title: In-China-for-Global Biologics: The Exciting Story of WuXi Biologics

Abstract: Biologics are transforming recent healthcare by addressing unmet medical needs, biologics discovery, development and manufacturing, however, requires significant expertise and investment. Prior to WuXi Biologics investment in biologics, China lags behind the global standards significantly. Over the past seven years, WuXi Biologics has successfully built a world-class biologics platform, developing 161 biologics concurrently from 100+ global clients. Recent approval of Taimed’s Trogarzo showcased ultimate success of the WuXi Biologics investment as it is the first company in China to obtain regulatory approval for commercial manufacturing of biologics in China.

Li Zhu, PhD
Chief Strategy Officer, Nanjing Legend Biotech and GenScript Biotechnology
Bio: Dr. Li Zhu, Chief Strategy Officer of Legend Biotech and GenScript, is in charge of corporate business strategy, in-license, strategic M&A, and new business development. Li obtained his bachelor degree in China in 1982 and his PhD degree at Stanford University in molecular biology and immunology in 1989. He worked at Clontech Laboratories in California from 1990 to 2000, successfully pioneered the commercialization of yeast two-hybrid system and a series of other advanced molecular biology techniques. He founded and managed Genetastix, a platform biotech company focusing on creating human antibody library in yeast and screening such library with genetic method. He returned to China in 2006 and worked at two biotech companies in Shanghai Zhangjiang High-tech Park before joining GenScript in 2010. He has been with GenScript since then. He has participated in the negotiation and final completion of Legend-Janssen BCMA – targeting CART therapy for Multiple Myeloma collaboration deal in 2017, a landmark business event between China biotech and US conglomerate pharma companies. Li has a business administration certificate from University of California, Berkeley.

Presentation Title: A world-class breakthrough in blood cancer treatment done by China biotech company Legend Biotech with CART cell therapy

Abstract: At 2017 ASCO conference in Chicago, Legend Biotech reported the result of preliminary clinical trials in multiple myeloma with its unique CART cell therapy technology. This report was heralded as one of the biggest news of 2017 ASCO and the most successful cancer treatment in the history. Since then many biggest pharma companies have been attracted to Nanjing for license and collaboration negotiation. By the end of 2017, we have concluded a deal with Janssen Pharmaceuticals for a 50:50 cost-and-profit-sharing, worldwide collaboration contract (70:30 in great China). The upfront payment from Janssen to Legend was $350M with additional escalating milestone payments. This deal also sets a big milestone in business development between a China biotech and a US conglomerate pharma companies. I will describe how Legend biotech develops from ground zero to a world class innovative cancer-fighting player.

Click Here for More Information

Contact: Jin Zhang
Contact Phone: 8474819282
Contact Email: zhangcat18@gmail.com

Event Address:

San Mateo Marriott, 1770 South Amphlett Blvd, San Mateo, CA 94402